News

Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) both are approaching a crucial moment in their stories. The biotech companies are awaiting regulatory decisions for

The stock market has rallied so far this year, particularly in the period between the last earnings season and this one. Companies now have to prove to Wall Street that their higher stock prices are

GSK (NYSE: GSK), a global healthcare company, initiated the separation of its consumer healthcare business, Haleon, last year, as part of its ambitious restructuring plan that CEO Emma Walmsley

AT&T (NYSE: T) posted its second-quarter report on July 26. Its revenue rose 1% year over year to $29.9 billion, which missed analysts' estimates by $30 million. Its adjusted earnings per share

Animal health company Zoetis (NYSE: ZTS) and pharmaceutical giant Eli Lilly (NYSE: LLY) are healthcare companies that are off to solid starts this year, with Zoetis' shares up more than 30% and

Investors haven't been a fan of AT&T (NYSE: T) stock in 2023, but that may be starting to change as performance begins to improve. In this video, Travis Hoium covers the latest numbers and why AT&T

It's been a tough few years for telecom giant AT&T (NYSE: T). In retrospect, its decisions to acquire DirecTV and then Time Warner were not only ill-advised, but expensive. Those deals have since

Dividend stocks can practically be a retiree's best friend. At least, the right ones can be. Three Motley Fool contributors were asked to identify healthcare dividend stocks they think retirees

Fool.com contributor Parkev Tatevosian reviews AT&T's (NYSE: T) latest earnings release to determine if it's an excellent dividend stock.

*Stock prices used were the afternoon prices of July 27

Image source: The Motley Fool.

AstraZeneca Plc (NASDAQ: AZN)Q2 2023 Earnings CallJul 28, 2023, 6:45 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of Genelux (NASDAQ: GNLX) were up 14.8% for the week, as of 9:30 a.m. ET Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech company's stock

Fool.com contributor Parkev Tatevosian compares Nano Dimension (NASDAQ: NNDM) and Invitae (NYSE: NVTA) across critical financial variables, including valuation, to determine the better stock to buy

Fool.com contributor Parkev Tatevosian compares AT&T (NYSE: T) and Broadcom (NASDAQ: AVGO) on dividend yield, operating profit margin, and forward price-to-earnings ratio to answer which stock is

Biotech stocks are famously volatile, and investors needed to look no further than the performance of Novocure's (NASDAQ: NVCR) shares on Thursday for proof. The company's share price cratered by

Image source: The Motley Fool.

AbbVie (NYSE: ABBV)Q2 2023 Earnings CallJul 27, 2023, 9:00 a.m. ET

Liz Shea

Continue reading

Source Fool.com

Shares of Evolus (NASDAQ: EOLS) were up more than 25% as of 11 a.m. ET after the company reported record quarterly revenue and increased guidance. The stock is up 31% so far this year.

Evolus is a

Even with government programs like Social Security, many people seek to save their own money for retirement, often setting the goal of reaching the $1 million mark by the time they reach retirement

On July 18, Pfizer (NYSE: PFE) announced that it is forging a strategic alliance with Flagship Pioneering, a venture capital (VC) firm, in which the pair would invest $50 million each into 10

Equity markets can be volatile, erratic, and not always entirely rational. That sometimes results in shares of companies not being adequately priced. And when these stocks trade for less than

Since the beginning of 2023, equity markets have been experiencing what could be the start of a bull run. Buying shares of growth stocks is an excellent move for investors looking to ride this wave

Both AT&T (NYSE: T) and Verizon (NYSE: VZ) are dealing with consumers who have become less willing to upgrade their smartphones and more willing to switch wireless providers. For Verizon, this has

When you think about biotech leaders, the name Biogen (NASDAQ: BIIB) may come to mind. Over the years, this biotechnology giant built a powerful multiple sclerosis (MS) treatment platform that has